10-Q: Silexion Therapeutics Narrows Losses, Boosts Cash

Silexion Therapeutics Corp. reported a significant reduction in net loss and a substantial increase in cash reserves for the nine months ended September 30, 2025, while addressing Nasdaq listing compliance and ongoing financing needs.

Summary

• Net loss for the nine months ended September 30, 2025, decreased by 49.3% to $7.5 million, compared to $14.8 million for the same period in 2024.
• Net loss for the three months ended September 30, 2025, decreased by 72.3% to $3.3 million, compared to $11.9 million for the same period in 2024.
• Cash and cash equivalents increased significantly to $9.243 million as of September 30, 2025, from $1.187 million at December 31, 2024.
• Total shareholders' equity turned positive, reaching $6.977 million as of September 30, 2025, from a deficit of $(3.989) million at December 31, 2024.
• Operating expenses decreased by 32.3% to $7.2 million for the nine months ended September 30, 2025, primarily due to lower non-cash share-based compensation.
• The company successfully regained compliance with Nasdaq listing standards, including minimum bid price and shareholders' equity requirements, and transferred to the Nasdaq Capital Market.
• Raised approximately $11.0 million gross from public offerings in January and September 2025, and an additional $5.0 million gross from warrant exercise inducement transactions in January and August 2025.
• Converted $1.8 million of the Related Party Promissory Note into 450,000 ordinary shares on September 15, 2025, though the Moringa Sponsor disputes this conversion.
• The company estimates its existing cash and cash equivalents are sufficient to fund business operations until the end of the second quarter of 2026.

Sentiment

Score: 6

Explanation: While the company demonstrated improved financial performance with reduced losses and increased cash, and successfully addressed Nasdaq listing issues, the explicit 'going concern' warning and the dispute with a related party regarding a promissory note conversion introduce substantial uncertainty and risk. The successful capital raises provide a temporary reprieve but highlight ongoing reliance on external funding.

Positives

• Significant reduction in net loss for both the three-month and nine-month periods ended September 30, 2025.
• Substantial increase in cash and cash equivalents to $9.243 million, providing improved liquidity.
• Achieved positive shareholders' equity of $6.977 million, a major improvement from a deficit.
• Successfully regained compliance with all Nasdaq listing standards and maintained its listing, albeit on the Nasdaq Capital Market.
• Successfully raised significant capital through public offerings and warrant exercises in 2025, totaling approximately $16.0 million gross.
• Increased authorized share capital to 9,000,000 ordinary shares, providing flexibility for future equity raises.
• Lead product candidate, SIL204, targets KRAS-mutated pancreatic cancer, a significant unmet medical need, building on positive Phase 2 results from a first-generation siRNA.

Negatives

• The company has incurred significant operating losses since inception and has not generated any revenue from product sales.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months without additional funding.
• Net cash used in operating activities increased to $7.8 million for the nine months ended September 30, 2025, from $5.5 million in the prior year, indicating higher cash burn from operations.
• The Moringa Sponsor disputes the conversion of $1.8 million of the Related Party Promissory Note and has demanded full repayment, which could lead to legal or financial complications.
• The company is subject to a mandatory Nasdaq panel monitor until September 23, 2026, with stricter consequences for future non-compliance with shareholders' equity requirements.
• Future equity financings are expected to cause significant dilution to current shareholders.

Risks

• Substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of the financial statements.
• The company is a development-stage company with a limited operating history and has never generated revenue from product sales, and may never be profitable.
• Need to raise substantial additional funding, which may not be available on acceptable terms or at all, and would likely cause dilution to shareholders.
• The approach to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products.
• Lack of experience producing product candidates at commercial levels, no marketing and sales organization, uncertain market receptiveness, and uncertainty regarding insurance coverage and reimbursement.
• Reliance on third parties (CROs and contract manufacturers) whose performance is largely beyond the company's control.
• Potential for significant dilution from future issuance of ordinary shares or other equity securities, including up to $13.17 million under the ATM Agreement, up to $100 million under the Shelf Registration Statement, conversion of the remaining $1.633 million A&R Sponsor Promissory Note, and shares underlying various warrants and the equity line of credit.
• The ongoing war in Israel, where the company's employees and management are located, could escalate and impact operations, despite current immaterial impact.
• Dispute with Moringa Sponsor regarding the conversion of the Related Party Promissory Note could lead to legal or financial challenges.
• Failure to maintain compliance with all Nasdaq Capital Market listing standards on an ongoing basis, especially during the mandatory panel monitoring period until September 23, 2026.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its lead product candidate, SIL204, through preclinical and clinical trials. Future plans include applying for Orphan Drug Designation in the U.S. and EU, conducting toxicological studies, initiating a statistically significant clinical trial, and seeking marketing approvals. The company anticipates financing these activities through a combination of public and private equity offerings, warrant exercises, and sales under its At-The-Market (ATM) agreement, but acknowledges no assurance of obtaining such funding on acceptable terms.

Management Comments

• Management is in the process of evaluating various financing alternatives, as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising. However, there is no assurance that the Company will be successful in obtaining such funding.
• We believe SIL204 has the potential to further improve clinical outcomes.
• We believe that the conversion [of the Related Party Promissory Note] was carried out in strict compliance with the substantive and procedural requirements of the note, and reject any claim to the contrary.

Industry Context

Silexion Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically targeting oncology with RNAi therapeutics. The focus on KRAS-mutated cancers positions the company in a challenging but potentially lucrative area, as KRAS is a well-known oncogene with significant unmet needs, particularly in pancreatic cancer where 92% of patients have this mutation. While many pharmaceutical companies pursue KRAS inhibition, Silexion's approach of silencing the oncogene itself via siRNA offers a differentiated strategy. The company's reliance on external funding and its development-stage status are typical for early-stage biotechs, but the 'going concern' warning highlights the inherent financial risks in this industry.

Comparison to Industry Standards

• The company's 'going concern' warning is a significant red flag, indicating a higher financial risk compared to more established, revenue-generating biotechnology firms.
• The substantial net losses are common for clinical-stage biotechnology companies like Silexion, which are heavily invested in R&D without product revenue. For example, many small-cap biotechs in early clinical phases often report annual losses in the tens of millions of dollars.
• The capital raising activities through public offerings and warrant exercises are standard practices for development-stage biotechs to fund operations and clinical trials, similar to how companies like Editas Medicine or Intellia Therapeutics have historically raised capital for their gene-editing platforms.
• The transfer from Nasdaq Global Market to Nasdaq Capital Market, while maintaining listing, suggests the company faced challenges meeting the more stringent listing requirements of the Global Market, a common occurrence for smaller companies with fluctuating market capitalization.
• The development of siRNA therapeutics for oncology, specifically targeting KRAS, places Silexion in a competitive landscape with larger players and other biotechs exploring RNA interference, such as Alnylam Pharmaceuticals (though Alnylam has approved products in other areas) or smaller firms like Mirati Therapeutics (focused on KRAS G12C inhibitors). Silexion's 'Integrated Treatment Regimen' with direct and systemic administration, building on previous Phase 2 data, aims to differentiate it from competitors.

Management Changes

Corporate Governance

Related Party Transactions

• The company issued a convertible promissory note (A&R Sponsor Promissory Note) in an original principal amount of $3,433,000 to Moringa Sponsor, LP.
• On September 15, 2025, $1,800,000 of the A&R Sponsor Promissory Note was converted into 450,000 ordinary shares.
• As of September 30, 2025, the remaining principal amount outstanding under the A&R Sponsor Promissory Note was $1,633,000.
• The Moringa Sponsor disputes the conversion of the $1.8 million and has demanded full repayment of the note.
• Greenstar, LP, an affiliate of the Moringa sponsor, participated in a PIPE financing, purchasing 1,482 Moringa ordinary shares (converted to New Silexion shares).
• EarlyBirdCapital, Inc. (EBC), the representative of the underwriters of Moringa's IPO, was issued an Underwriters Promissory Note of $1.25 million, which was fully repaid/converted by March 18, 2025.

Stakeholder Impact

• Shareholders face significant potential dilution from ongoing and future equity financing activities (public offerings, warrant exercises, ATM sales). The dispute with Moringa Sponsor could also impact shareholder value.
• Employees: The company expects to hire additional personnel for R&D and general administration, indicating potential growth opportunities. Share-based compensation is a component of employee remuneration.
• Creditors: The Moringa Sponsor, as a creditor holding a promissory note, is in dispute with the company over a conversion, which could affect its repayment.
• Regulatory Authorities (Nasdaq): The company successfully addressed listing deficiencies but remains under a mandatory panel monitor, requiring strict adherence to listing standards.

Next Steps

• Initiate clinical studies for SIL204, contingent upon obtaining regulatory clearance.
• Apply for Orphan Drug Designation in both the U.S. and EU for SIL204.
• Continue conducting toxicological studies with respect to SIL204.
• Initiate a clinical trial powered for statistical significance with respect to SIL204.
• Seek marketing approvals for SIL204 in various territories.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional operational, clinical, quality control, and scientific personnel.
• Add additional product candidates to the pipeline.
• Add operational, financial, and management information systems and personnel.
• Invest in research and development and regulatory approval efforts to utilize the technology as a platform.
• Potentially sell ordinary shares under the ATM Agreement to finance ongoing operations.
• Address the dispute with the Moringa Sponsor regarding the conversion of the Related Party Promissory Note.
• Maintain compliance with all Nasdaq Capital Market listing standards, especially during the mandatory panel monitoring period until September 23, 2026.

Key Dates

Recommendation

While Silexion Therapeutics has shown significant improvement in reducing net losses and substantially increasing its cash position through successful capital raises, the explicit 'going concern' warning and the ongoing dispute with a major related party (Moringa Sponsor) introduce considerable financial and operational uncertainty. The company's ability to fund its operations beyond Q2 2026 is contingent on further successful financing, which will likely lead to significant shareholder dilution. The transfer to the Nasdaq Capital Market and ongoing monitoring also indicate a higher risk profile. Given the early clinical stage of its lead product candidate, SIL204, and the inherent risks of drug development, a 'hold' recommendation is appropriate. Investors should monitor the resolution of the related party dispute, progress in clinical trials, and the company's ability to secure additional non-dilutive or less dilutive funding.

Keywords

Silexion Therapeutics, SLXN, Biotechnology, Oncology, KRAS, RNAi therapeutics, SIL204, Pancreatic cancer, SEC filing, 10-Q, Financial results, Nasdaq listing, Capital raise, Warrants, Clinical stage, Going concern, Biopharma